Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial
Introduction Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3–5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical...
Saved in:
Main Authors: | Simon Broadley, Berzenn Urbi, Richard Bedlack, Ethan Russo, Arman Sabet |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-11-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/9/11/e029449.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dysregulation of the Autophagy-Endolysosomal System in Amyotrophic Lateral Sclerosis and Related Motor Neuron Diseases
by: Asako Otomo, et al.
Published: (2012-01-01) -
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease
by: Kaili Ou, et al.
Published: (2025-01-01) -
Impairments of inhibitory neurons in amyotrophic lateral sclerosis and frontotemporal dementia
by: Félicie Lorenc, et al.
Published: (2024-12-01) -
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
by: Matthew C Kiernan, et al.
Published: (2021-01-01) -
Pain in Amyotrophic Lateral Sclerosis Is Underrated
by: Soyoung Kwak, et al.
Published: (2024-12-01)